免费获得国外相关药品，最快 1 个工作日回馈药物信息

出境医 / 临床实验 / A Study Lasmiditan (LY573144) in a Single Migraine Attack in Japanese Participants With Migraine (MONONOFU)

A Study Lasmiditan (LY573144) in a Single Migraine Attack in Japanese Participants With Migraine (MONONOFU)

Study Description
Brief Summary:
This study will assess the efficacy and safety of lasmiditan in the acute treatment of a migraine attack in Japanese adult participants with or without aura.

Condition or disease Intervention/treatment Phase
Migraine Drug: Lasmiditan Drug: Placebo Phase 2

Study Design
Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 846 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: RandoMized, DOuble-bliNd, PlacebO-coNtrolled Trial Of Lasmiditan in a Single Migraine Attack in Japanese Patients SuFfering From Migraine With or WithoUt Aura - the MONONOFU Study
Actual Study Start Date : May 31, 2019
Actual Primary Completion Date : June 8, 2020
Actual Study Completion Date : June 8, 2020
Arms and Interventions
Arm Intervention/treatment
Experimental: 50 milligram (mg) Lasmiditan
50 mg Lasmiditan tablet plus two placebo tablets (to match Lasmiditan dose) administered once orally to treat a single migraine attack.
 Drug: Lasmiditan
Administered orally
Other Name: LY573144

Drug: Placebo
Administered orally
Experimental: 100 mg Lasmiditan
100 mg Lasmiditan tablet plus two placebo tablets (to match Lasmiditan dose) administered once orally to treat a single migraine attack.
 Drug: Lasmiditan
Administered orally
Other Name: LY573144

Drug: Placebo
Administered orally
Experimental: 200 mg Lasmiditan
200 mg Lasmiditan (two 100 mg tablets) plus one placebo tablet (to match Lasmiditan dose) administered once orally to treat a single migraine attack.
 Drug: Lasmiditan
Administered orally
Other Name: LY573144

Drug: Placebo
Administered orally
Placebo Comparator: Placebo
Placebo tablets (to match 50 mg, 100 mg, 200 mg Lasmiditan dose tablets) administered once orally to treat a single migraine attack.
 Drug: Placebo
Administered orally
Outcome Measures
Primary Outcome Measures :
  1. Percentage of Participants Who Are Headache Pain Free In High Dose Group (200 mg Lasmiditan) [ Time Frame: 2 Hours Postdose ]
    Percentage of participants who were headache pain free (defined as moderate or severe pain becoming none) at 2 hours postdose.


Secondary Outcome Measures :
  1. Percentage of Participants Who Are Headache Pain Free in Each Dose Group [ Time Frame: 2 Hours Postdose ]
    Percentage of participants who are headache pain free in each dose group at 2 hours postdose.

  2. Percentage of Participants With Headache Pain Relief [ Time Frame: 2 Hours Postdose ]
    Percentage of participants with headache pain relief (defined as moderate or severe headache pain becoming mild or none) at 2 hours postdose.

  3. Percentage of Participants Who Are Free of Most Bothersome Symptoms (MBS) Associated With Migraine [ Time Frame: 2 Hours Postdose ]

    Percentage of participants defined as the associated symptom present and identified as MBS (nausea, photophobia, or phonophobia) prior to dosing and being absent at 2 hours postdose.

    Missing value at a particular time point was considered as "nonresponder."


  4. Percentage of Participants With 24-Hour Sustained Pain Freedom [ Time Frame: 24 Hours Postdose ]
    Percentage of participants who are headache pain free at 2 hours postdose and 24 hours postdose with no rescue medication.

  5. Percentage of Participants With 48-Hour Sustained Pain Freedom [ Time Frame: 48 Hours Postdose ]
    Percentage of participants who are headache pain free at 2 hours postdose and 48 hours postdose with no rescue medication.

  6. Percentage of Participants That Are Free of Phonophobia [ Time Frame: 2 Hours Postdose ]
    Percentage of participants that are free of phonophobia at 2 hours postdose.

  7. Percentage of Participants That Are Free of Photophobia [ Time Frame: 2 Hours Postdose ]
    Percentage of participants that are free of photophobia at 2 hours postdose.

  8. Percentage of Participants That Are Free of Nausea [ Time Frame: 2 Hours Postdose ]
    Percentage of participants that are free of nausea at 2 hours postdose.

  9. Percentage of Participants That Are Free of Vomiting [ Time Frame: 2 Hours Postdose ]
    Percentage of participants that are free of vomiting at 2 hours postdose.

  10. Percentage of Participants With Pain Freedom [ Time Frame: 1 Hour Postdose ]
    Percentage of participants with pain freedom.

  11. Percentage of Participants With Headache Pain Relief [ Time Frame: 1 Hour Postdose ]
    Percentage of participants with headache pain relief at 1 hour postdose.

  12. Percentage of Participants With Freedom From Most Bothersome Symptom (MBS) [ Time Frame: 1 Hour Postdose ]
    Percentage of participants defined as the associated symptom present and identified as MBS (nausea, photophobia, or phonophobia) prior to dosing and being absent at 1 hour postdose.

  13. Percentage of Participants With No Disability [ Time Frame: 1 Hour Postdose ]

    Disability will be measured by determining the level of interference with normal activities with 4 response options including: not at all (0); mild interference (1), marked interference (2); and need complete bed rest (3). No Disability timing is defined as the first time when severity becomes 0.

    Percentage of participants who are responders defined as score = 0 at 1 hours postdose.


  14. Percentage of Participants With No Disability [ Time Frame: 2 Hours Postdose ]

    Disability will be measured by determining the level of interference with normal activities with 4 response options including not at all (0); mild interference (1), marked interference (2); and need complete bed rest (3). No Disability timing is defined as the first time when severity becomes 0.

    Percentage of participants who are responders defined as score = 0 at 2 hours postdose.


  15. Change From Baseline on the EuroQol 5 Dimension 5-level Scale (EQ-5D-5L) Health Status Index Score Japan [ Time Frame: 24 Hours Postdose ]
    The EQ-5D-5L was assessed based the EQ-5D-5L Health Status Index Score. The Japan specific tariffs (Japanese population-based index value) was used. The EQ-5D-5L is a participant rated, 2-part questionnaire. The first part assesses 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) that have 5 levels (no problems, slight problems, moderate problems, severe problems, and extreme problems). The health state index score was calculated based on the responses to the 5 dimensions, providing a single value on a scale from less than 0 (where 0 is a health state equivalent to death; negative values are valued as worse than death) to 1 (perfect health), with higher scores indicating better health utility.

  16. Change From Baseline on the EuroQol 5 Dimension 5-level Scale (EQ-5D-5L) Visual Analog Scale [ Time Frame: 24 Hours Postdose ]
    The EQ-5D-5L is a participant rated, 2-part questionnaire.The second part of the questionnaire consists of a visual analog scale on which the participant rates their perceived health state from 0 (the worst health you can imagine) to 100 (the best health you can imagine).

  17. Percentage of Participants With Very Much or Much Better as Measured by the Patient Global Impression of Change (PGI-C) [ Time Frame: 2 Hours Postdose ]
    The PGI-C is a one-item questionnaire that asks participants to provide their impression of change since taking the medicine. The PGI-C is measured using a 7-point Likert scale, with 1 = very much better, 2 = much better, 3 = a little better, 4 = no change, 5 = a little worse, 6 = much worse, and 7 = very much worse. Percentage of participants who are responders defined as having rated their impression of change as "very much better" or "much better" at 2 hours postdose.

  18. Health-Related Quality of Life (HRQoL) Total Score as Measured by the 24-Hour Migraine Quality of Life Questionnaire (MQoLQ) [ Time Frame: 24 Hours Postdose ]
    The HRQoL is a 15-item, self-administered questionnaire. The items cover 5 domains (work functioning, social functioning, energy and vitality, feelings and concerns, and migraine symptoms). Each domain consists of 3 questions answered on a 7-point scale there 1 indicates maximum impairment and 7 indicating no impairment. A domain score is calculated by summing the responses to the 3 questions and the domain score ranges from 3 to 21, where a lower score indicates greater impairment, and a higher score indicates less impairment. The questionnaire will be administered 24 hours after the study drug.


Eligibility Criteria
Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Participants with migraine with or without aura fulfilling the International Classification of Headache Disorders (ICHD)-2.
  • History of disabling migraine for at least 1 year.
  • Migraine Disability Assessment Test (MIDAS) score ≥11.
  • Migraine onset before the age of 50 years.
  • History of 3-8 migraine attacks per month and <15 headache days per month during the past 3 months.

Exclusion Criteria:

  • Known hypersensitivity to lasmiditan, or to any excipient of lasmiditan oral tablets.
  • History or evidence of hemorrhagic stroke, epilepsy, or any other condition placing the patient at increased risk of seizures.
  • History of recurrent dizziness and/or vertigo including benign paroxysmal positional vertigo, Meniere's disease, vestibular migraine, and other vestibular disorders.
  • History of diabetes mellitus with complications (diabetic retinopathy, nephropathy, or neuropathy).
  • History of orthostatic hypotension with syncope.
Contacts and Locations

Locations
Show Show 34 study locations
Sponsors and Collaborators
Eli Lilly and Company
Investigators
Layout table for investigator information
Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) Eli Lilly and Company
Tracking Information
First Submitted Date  ICMJE May 23, 2019
First Posted Date  ICMJE May 24, 2019
Results First Submitted Date  ICMJE April 9, 2021
Results First Posted Date  ICMJE May 5, 2021
Last Update Posted Date May 5, 2021
Actual Study Start Date  ICMJE May 31, 2019
Actual Primary Completion Date June 8, 2020   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: April 9, 2021) 		Percentage of Participants Who Are Headache Pain Free In High Dose Group (200 mg Lasmiditan) [ Time Frame: 2 Hours Postdose ]
Percentage of participants who were headache pain free (defined as moderate or severe pain becoming none) at 2 hours postdose.
Original Primary Outcome Measures  ICMJE
 (submitted: May 23, 2019) 		Percentage of Participants who are Pain Free (High Dose) [ Time Frame: 2 Hours Postdose ]
Percentage of Participants who are Pain Free (High Dose)
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: April 9, 2021)
  • Percentage of Participants Who Are Headache Pain Free in Each Dose Group [ Time Frame: 2 Hours Postdose ]
    Percentage of participants who are headache pain free in each dose group at 2 hours postdose.
  • Percentage of Participants With Headache Pain Relief [ Time Frame: 2 Hours Postdose ]
    Percentage of participants with headache pain relief (defined as moderate or severe headache pain becoming mild or none) at 2 hours postdose.
  • Percentage of Participants Who Are Free of Most Bothersome Symptoms (MBS) Associated With Migraine [ Time Frame: 2 Hours Postdose ]
    Percentage of participants defined as the associated symptom present and identified as MBS (nausea, photophobia, or phonophobia) prior to dosing and being absent at 2 hours postdose. Missing value at a particular time point was considered as "nonresponder."
  • Percentage of Participants With 24-Hour Sustained Pain Freedom [ Time Frame: 24 Hours Postdose ]
    Percentage of participants who are headache pain free at 2 hours postdose and 24 hours postdose with no rescue medication.
  • Percentage of Participants With 48-Hour Sustained Pain Freedom [ Time Frame: 48 Hours Postdose ]
    Percentage of participants who are headache pain free at 2 hours postdose and 48 hours postdose with no rescue medication.
  • Percentage of Participants That Are Free of Phonophobia [ Time Frame: 2 Hours Postdose ]
    Percentage of participants that are free of phonophobia at 2 hours postdose.
  • Percentage of Participants That Are Free of Photophobia [ Time Frame: 2 Hours Postdose ]
    Percentage of participants that are free of photophobia at 2 hours postdose.
  • Percentage of Participants That Are Free of Nausea [ Time Frame: 2 Hours Postdose ]
    Percentage of participants that are free of nausea at 2 hours postdose.
  • Percentage of Participants That Are Free of Vomiting [ Time Frame: 2 Hours Postdose ]
    Percentage of participants that are free of vomiting at 2 hours postdose.
  • Percentage of Participants With Pain Freedom [ Time Frame: 1 Hour Postdose ]
    Percentage of participants with pain freedom.
  • Percentage of Participants With Headache Pain Relief [ Time Frame: 1 Hour Postdose ]
    Percentage of participants with headache pain relief at 1 hour postdose.
  • Percentage of Participants With Freedom From Most Bothersome Symptom (MBS) [ Time Frame: 1 Hour Postdose ]
    Percentage of participants defined as the associated symptom present and identified as MBS (nausea, photophobia, or phonophobia) prior to dosing and being absent at 1 hour postdose.
  • Percentage of Participants With No Disability [ Time Frame: 1 Hour Postdose ]
    Disability will be measured by determining the level of interference with normal activities with 4 response options including: not at all (0); mild interference (1), marked interference (2); and need complete bed rest (3). No Disability timing is defined as the first time when severity becomes 0. Percentage of participants who are responders defined as score = 0 at 1 hours postdose.
  • Percentage of Participants With No Disability [ Time Frame: 2 Hours Postdose ]
    Disability will be measured by determining the level of interference with normal activities with 4 response options including not at all (0); mild interference (1), marked interference (2); and need complete bed rest (3). No Disability timing is defined as the first time when severity becomes 0. Percentage of participants who are responders defined as score = 0 at 2 hours postdose.
  • Change From Baseline on the EuroQol 5 Dimension 5-level Scale (EQ-5D-5L) Health Status Index Score Japan [ Time Frame: 24 Hours Postdose ]
    The EQ-5D-5L was assessed based the EQ-5D-5L Health Status Index Score. The Japan specific tariffs (Japanese population-based index value) was used. The EQ-5D-5L is a participant rated, 2-part questionnaire. The first part assesses 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) that have 5 levels (no problems, slight problems, moderate problems, severe problems, and extreme problems). The health state index score was calculated based on the responses to the 5 dimensions, providing a single value on a scale from less than 0 (where 0 is a health state equivalent to death; negative values are valued as worse than death) to 1 (perfect health), with higher scores indicating better health utility.
  • Change From Baseline on the EuroQol 5 Dimension 5-level Scale (EQ-5D-5L) Visual Analog Scale [ Time Frame: 24 Hours Postdose ]
    The EQ-5D-5L is a participant rated, 2-part questionnaire.The second part of the questionnaire consists of a visual analog scale on which the participant rates their perceived health state from 0 (the worst health you can imagine) to 100 (the best health you can imagine).
  • Percentage of Participants With Very Much or Much Better as Measured by the Patient Global Impression of Change (PGI-C) [ Time Frame: 2 Hours Postdose ]
    The PGI-C is a one-item questionnaire that asks participants to provide their impression of change since taking the medicine. The PGI-C is measured using a 7-point Likert scale, with 1 = very much better, 2 = much better, 3 = a little better, 4 = no change, 5 = a little worse, 6 = much worse, and 7 = very much worse. Percentage of participants who are responders defined as having rated their impression of change as "very much better" or "much better" at 2 hours postdose.
  • Health-Related Quality of Life (HRQoL) Total Score as Measured by the 24-Hour Migraine Quality of Life Questionnaire (MQoLQ) [ Time Frame: 24 Hours Postdose ]
    The HRQoL is a 15-item, self-administered questionnaire. The items cover 5 domains (work functioning, social functioning, energy and vitality, feelings and concerns, and migraine symptoms). Each domain consists of 3 questions answered on a 7-point scale there 1 indicates maximum impairment and 7 indicating no impairment. A domain score is calculated by summing the responses to the 3 questions and the domain score ranges from 3 to 21, where a lower score indicates greater impairment, and a higher score indicates less impairment. The questionnaire will be administered 24 hours after the study drug.
Original Secondary Outcome Measures  ICMJE
 (submitted: May 23, 2019)
  • Percentage of Participants who are Pain Free in Each Dose Group [ Time Frame: 2 Hours Postdose ]
    Percentage of Participants who are Pain Free in Each Dose Group
  • Percentage of Participants with Pain Relief [ Time Frame: 2 Hours Postdose ]
    Percentage of Participants with Pain Relief
  • Percentage of Participants who are Free of MBS Associated with Migraine [ Time Frame: 2 Hours Postdose ]
    Percentage of Participants who are Free of the Most Bothersome Symptom as Identified by the Individual from the Associated Symptoms of Nausea, Phonophobia or Photophobia (MBS) Associated with Migraine
  • Percentage of Participants With 24-Hour Sustained Pain Freedom [ Time Frame: 24 Hours ]
    Sustained pain freedom defined as pain free at 2 and 24 hours with no rescue medication.
  • Percentage of Participants With 48-Hour Sustained Pain Freedom [ Time Frame: 48 Hours ]
    Sustained pain freedom defined as pain free at 2 and 48 hours with no rescue medication.
  • Percentage of Participants That Are Free of Phonophobia [ Time Frame: 2 Hours Postdose ]
    Percentage of Participants that are Free of Phonophobia
  • Percentage of Participants That Are Free of Photophobia [ Time Frame: 2 Hours Postdose ]
    Percentage of Participants that are Free of Photophobia
  • Percentage of Participants That Are Free of Nausea [ Time Frame: 2 Hours Postdose ]
    Percentage of Participants that are Free of Nausea
  • Percentage of Participants That Are Free of Vomiting [ Time Frame: 2 Hours Postdose ]
    Percentage of Participants that are Free of Vomiting
  • Percentage of Participants With Pain Freedom [ Time Frame: 1 Hour Postdose ]
    Percentage of Participants with Pain Freedom
  • Percentage of Participants with Pain Relief [ Time Frame: 1 Hour Postdose ]
    Percentage of Participants with Pain Relief
  • Percentage of Participants with Freedom from MBS [ Time Frame: 1 Hour Postdose ]
    Percentage of Participants with Freedom from MBS
  • Percentage of Participants With No Disability [ Time Frame: 1 Hour Postdose ]
    Percentage of Participants with No Disability
  • Percentage of Participants With No Disability [ Time Frame: 2 Hours Postdose ]
    Percentage of Participants with No Disability
  • Change from Baseline on the EuroQol 5 Dimension 5-level scale (EQ-5D-5L) [ Time Frame: 24 Hours Postdose ]
    Change from Baseline on the EQ-5D-5L
  • Percentage of Participants Very Much or Much Better as Measured by the Patient Global Impression of Change (PGI-C) [ Time Frame: 2 Hours Postdose ]
    Percentage of Participants Very Much or Much Better as Measured by the PGI-C
  • Health-Related Quality of Life (HRQoL) Total Score as Measured by the 24-Hour Migraine Quality of Life Questionnaire (MQoLQ) [ Time Frame: 24 Hours Postdose ]
    HRQoL Total Score as Measured by the 24-Hour MQoLQ
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE A Study Lasmiditan (LY573144) in a Single Migraine Attack in Japanese Participants With Migraine
Official Title  ICMJE RandoMized, DOuble-bliNd, PlacebO-coNtrolled Trial Of Lasmiditan in a Single Migraine Attack in Japanese Patients SuFfering From Migraine With or WithoUt Aura - the MONONOFU Study
Brief Summary This study will assess the efficacy and safety of lasmiditan in the acute treatment of a migraine attack in Japanese adult participants with or without aura.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Condition  ICMJE Migraine
Intervention  ICMJE
  • Drug: Lasmiditan
    Administered orally
    Other Name: LY573144
  • Drug: Placebo
    Administered orally
Study Arms  ICMJE
  • Experimental: 50 milligram (mg) Lasmiditan
    50 mg Lasmiditan tablet plus two placebo tablets (to match Lasmiditan dose) administered once orally to treat a single migraine attack.
    Interventions:
    • Drug: Lasmiditan
    • Drug: Placebo
  • Experimental: 100 mg Lasmiditan
    100 mg Lasmiditan tablet plus two placebo tablets (to match Lasmiditan dose) administered once orally to treat a single migraine attack.
    Interventions:
    • Drug: Lasmiditan
    • Drug: Placebo
  • Experimental: 200 mg Lasmiditan
    200 mg Lasmiditan (two 100 mg tablets) plus one placebo tablet (to match Lasmiditan dose) administered once orally to treat a single migraine attack.
    Interventions:
    • Drug: Lasmiditan
    • Drug: Placebo
  • Placebo Comparator: Placebo
    Placebo tablets (to match 50 mg, 100 mg, 200 mg Lasmiditan dose tablets) administered once orally to treat a single migraine attack.
    Intervention: Drug: Placebo
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: July 21, 2020) 		846
Original Estimated Enrollment  ICMJE
 (submitted: May 23, 2019) 		880
Actual Study Completion Date  ICMJE June 8, 2020
Actual Primary Completion Date June 8, 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Participants with migraine with or without aura fulfilling the International Classification of Headache Disorders (ICHD)-2.
  • History of disabling migraine for at least 1 year.
  • Migraine Disability Assessment Test (MIDAS) score ≥11.
  • Migraine onset before the age of 50 years.
  • History of 3-8 migraine attacks per month and <15 headache days per month during the past 3 months.

Exclusion Criteria:

  • Known hypersensitivity to lasmiditan, or to any excipient of lasmiditan oral tablets.
  • History or evidence of hemorrhagic stroke, epilepsy, or any other condition placing the patient at increased risk of seizures.
  • History of recurrent dizziness and/or vertigo including benign paroxysmal positional vertigo, Meniere's disease, vestibular migraine, and other vestibular disorders.
  • History of diabetes mellitus with complications (diabetic retinopathy, nephropathy, or neuropathy).
  • History of orthostatic hypotension with syncope.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Japan
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03962738
Other Study ID Numbers  ICMJE 17012
H8H-JE-LAIH ( Other Identifier: Eli Lilly and Company )
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
IPD Sharing Statement  ICMJE
Plan to Share IPD: Yes
Plan Description: Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting Materials: Study Protocol
Supporting Materials: Statistical Analysis Plan (SAP)
Supporting Materials: Clinical Study Report (CSR)
Time Frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access Criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
URL: https://vivli.org/
Responsible Party Eli Lilly and Company
Study Sponsor  ICMJE Eli Lilly and Company
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) Eli Lilly and Company
PRS Account Eli Lilly and Company
Verification Date July 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP

治疗医院

新药特效药

前沿医讯